# CKD-MBD

## Cinacalcet

```{block2, type='box_landmark'}
[**EVOLVE**](https://www.ncbi.nlm.nih.gov/pubmed/23121374) (2012): ![](Logo_RCT.png){height=1.2em} ![](Logo_SEM.png){height=1.2em} - cinacalcet *vs.* placebo in CKD5D. No significant difference in primary outcome (cardiovascular disease composite) over \~20 months.  

```

## Phosphate binders

Do **calcium-containing binders** cause worse hard outcomes?

[**DCOR**](https://www.ncbi.nlm.nih.gov/pubmed/17728707) (2007): ![](Logo_RCT.png){height=1.2em} - sevelamer *vs.* calcium-based binders.  No difference in overall mortality.  

[**Jamal et al.**](https://www.ncbi.nlm.nih.gov/pubmed/23870817) (2013): ![](Logo_MET.png){height=1.2em} - meta-analysis of 11 RCTs comparing calcium-based with non-calcium-based phosphate binders.  Non-calcium-based binders had lower all-cause mortality (RR 0.78, 0.61--0.98).  

**LANDMARK**: ![](Logo_RCT.png){height=1.2em} - Lanthanum *vs.* calcium in HD patients.  Not yet published (but presented at ASN 2018 - no difference between two groups).  
